British American Tobacco has withdrawn its nicotine pouch products from the French market following the implementation of a nationwide ban on oral nicotine products. The move comes in response to a government decree that took effect in April 2026, prohibiting the sale and distribution of such products. At the same time, the company has strongly criticised the decision, arguing that the ban was introduced without parliamentary debate or broader consultation. BAT contends that the measure runs counter to harm reduction strategies and could undermine efforts to reduce smoking rates by limiting access to lower-risk alternatives. The development highlights ongoing tensions between national regulatory approaches and wider European discussions on how to manage emerging nicotine products within a coherent public health framework.

A recent qualitative risk assessment examining the carcinogenic potential of e-cigarettes has sparked strong reactions among public health experts and researchers. While the study suggests possible links between vaping and cancer-related mechanisms, several scientists have criticised its methodology and interpretation of evidence. Experts highlight that the review does not directly compare vaping with smoking, which they argue is essential for understanding relative risk. They also point out that detecting trace levels of potentially harmful substances does not necessarily translate into meaningful health risk, particularly without considering dosage and real-world exposure. Concerns have been raised about selective use of evidence and the absence of clear criteria for assessing causality, leading some to question the reliability of the conclusions. At the same time, researchers emphasise that while vaping is not risk-free, current evidence indicates significantly lower exposure to carcinogens compared to smoking. The debate reflects broader tensions in interpreting emerging evidence and communicating risk, particularly in areas where long-term epidemiological data are still limited.

Growing criticism is emerging over proposals to extend smoking-style bans to vaping in public places, with some commentators arguing that such measures lack a solid scientific basis. Critics point to existing evidence suggesting that second-hand exposure to vapour poses minimal risk to bystanders, questioning the justification for stricter restrictions. Concerns are also being raised that expanding bans could blur the distinction between smoking and vaping, potentially discouraging smokers from switching to lower-risk alternatives. The argument further suggests that implementing such policies may lead to unintended consequences, including reinforcing misconceptions about relative harm and misallocating public resources. At the centre of the debate is a broader question about whether public health policy should prioritise precautionary restrictions or remain closely aligned with existing scientific evidence on risk and exposure.

Growing debate is emerging around how nicotine is perceived in public health discussions, with some commentators arguing that it is often wrongly identified as the primary cause of smoking-related harm. The central claim is that it is the act of combustion—burning tobacco—that produces the vast majority of toxic chemicals responsible for disease, rather than nicotine itself. This perspective suggests that conflating nicotine with smoking risks misleading the public and obscuring the potential role of lower-risk alternatives in reducing harm. Proponents argue that clearer communication around relative risks could support more effective strategies to reduce smoking-related illness. At the same time, the issue remains contentious, particularly given nicotine’s addictive nature and concerns about uptake among non-smokers. The discussion reflects a broader divide in public health between precautionary approaches and harm reduction strategies.

France has introduced one of the strictest approaches in Europe to nicotine pouches, with new rules criminalising not only their sale but also personal possession and use. As of April 2026, these products are classified as a “toxic substance” under a health ministry decree, placing them under severe legal restrictions. Unlike in most other countries, individuals found in possession of nicotine pouches could face significant penalties, including large fines and even prison sentences under existing public health laws. The ban also extends beyond pouches to cover other non-medicinal oral nicotine products, while exempting approved nicotine replacement therapies. This move highlights an increasingly strict regulatory stance in France, and has sparked wider debate about proportionality, enforcement, and the role of alternative nicotine products within public health policy.